Get the Stockscreener App
3.39
0.29%
-0.010
Oramed Pharmaceuticals Inc stock is traded at $3.39, with a volume of 108.79K.
It is down -0.29% in the last 24 hours and down -0.73% over the past month.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
See More
Previous Close:
$3.40
Open:
$3.42
24h Volume:
108.79K
Relative Volume:
0.54
Market Cap:
$137.11M
Revenue:
$2.00M
Net Income/Loss:
$63.21M
P/E Ratio:
2.2824
EPS:
1.4853
Net Cash Flow:
$-9.71M
1W Performance:
-3.14%
1M Performance:
-0.73%
6M Performance:
+32.94%
1Y Performance:
+59.15%
1-Day Range:
$3.31
$3.4699
1-Week Range:
$3.23
$3.53
52-Week Range:
$1.82
$3.76
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Name
Oramed Pharmaceuticals Inc
Sector
Industry
Phone
646-844-1164
Address
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Compare ORMP vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
3.39 | 137.11M | 2.00M | 63.21M | -9.71M | 1.4853 |
VRTX
Vertex Pharmaceuticals Inc
|
447.26 | 113.62B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
777.25 | 82.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
743.12 | 46.12B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.73 | 43.60B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
164.86 | 35.54B | 606.42M | -1.28B | -997.58M | -6.403 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-20-21 | Initiated | Canaccord Genuity | Buy |
| Feb-09-21 | Initiated | National Securities | Buy |
| Dec-03-20 | Initiated | Alliance Global Partners | Buy |
| Mar-11-20 | Initiated | Aegis Capital | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-17 | Resumed | B. Riley FBR, Inc. | Buy |
| May-26-16 | Reiterated | FBR Capital | Outperform |
| Dec-01-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-19-15 | Initiated | FBR Capital | Outperform |
| Apr-13-15 | Resumed | MLV & Co | Buy |
| Jan-30-14 | Reiterated | Aegis Capital | Buy |
| Jan-08-14 | Reiterated | Aegis Capital | Buy |
| Jan-08-14 | Initiated | MLV & Co | Buy |
| Dec-03-13 | Initiated | Aegis Capital | Buy |
View All
Oramed Pharmaceuticals Inc Stock (ORMP) Latest News
ABOS Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai
Oramed Completes Oratech Sale and Strategic Lifeward Financing - TipRanks
Oramed (ORMP) completes Oratech sale and buys $9M Lifeward notes - Stock Titan
Oramed (NASDAQ: ORMP) CSO uses 435,084 shares to cover RSU tax - Stock Titan
Oramed (NASDAQ: ORMP) CEO uses 44,818 shares to cover RSU tax withholding - Stock Titan
FOMO Trade: Is Oramed Pharmaceuticals Inc stock good for income investorsMarket Sentiment Report & Entry and Exit Point Strategies - baoquankhu1.vn
Oramed Pharmaceuticals (ORMP) price target increased by 92.31% to 6.38 - MSN
Oramed Pharmaceuticals (NASDAQ:ORMP) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Oramed Pharmaceuticals: Oral Insulin Technology, Strategic Investments, and 2026 Business Overview - Minichart
Oramed: Q4 Earnings Snapshot - Barchart
Oramed Pharmaceuticals 2025 10-K: $2.0M Revenue, $1.50 Diluted EPS - TradingView
Oramed (NASDAQ: ORMP) pivots with Lifeward deal and Alpha Tau stake - Stock Titan
Lifeward closes Oramed partnership, secures $10 million funding By Investing.com - Investing.com Australia
Lifeward Closes Oramed Partnership, Acquires Oratech Pharma - Moomoo
Lifeward closes Oramed partnership, secures $10 million funding - Investing.com
Lifeward Successfully Closes on Strategic Partnership with Oramed - manilatimes.net
Lifeward adds biotech drug-delivery tech and taps up to $47M - Stock Titan
Lifeward Ltd. completed the acquisition of Oratech Pharma, Inc. from Oramed Pharmaceuticals Inc.. - MarketScreener
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Oramed Pharmaceuticals Inc expected to post breakeven results a shareEarnings Preview - TradingView
Surprises Report: Does Oramed Pharmaceuticals Inc stock benefit from AI growth2026 Macro Impact & Pattern Based Trade Signal System - baoquankhu1.vn
Oramed Pharmaceuticals (ORMP) to Release Earnings on Thursday - MarketBeat
Market Overview: What is Oramed Pharmaceuticals Incs 5 year growth outlookEarnings Growth Report & High Accuracy Swing Entry Alerts - baoquankhu1.vn
[Form 4] ORAMED PHARMACEUTICALS INC. Insider Trading Activity - Stock Titan
Oramed (NASDAQ: ORMP) CEO receives 167,005 RSUs vesting from 2026 - Stock Titan
Oramed (NASDAQ: ORMP) COO receives 95,889 RSUs vesting from 2026 - Stock Titan
Oramed (NASDAQ: ORMP) CFO receives 95,889 RSU equity award - Stock Titan
Oramed deal reshapes Lifeward (NASDAQ: LFWD) with new tech and funding - Stock Titan
Oral insulin and robotic exoskeletons: Lifeward’s $47M pivot - Stock Titan
Retail Trends: How sensitive is Oramed Pharmaceuticals Inc to inflationWeekly Trade Recap & Low Risk Entry Point Guides - baoquankhu1.vn
Is Oramed Pharmaceuticals Inc stock undervalued right nowEarnings Risk Report & Verified Momentum Watchlists - baoquankhu1.vn
Returns Recap: Is Oramed Pharmaceuticals Inc stock a smart retirement pickMarket Volume Report & High Yield Stock Recommendations - baoquankhu1.vn
Oramed (ORMP) CEO donates 100,000 shares to charity - Stock Titan
Lifeward shareholders approve Oramed partnership deal By Investing.com - Investing.com India
Lifeward shareholders approve Oramed partnership deal - Investing.com
Lifeward Partners with Oramed to Enhance Biotech Portfolio and Drive Path to Profitability - Quiver Quantitative
Lifeward Receives Shareholder Approval to Close on - GlobeNewswire
Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed-Creating Diversified Biomedical Company - Bitget
LFWD Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Gains Report: What is the target price for Oramed Pharmaceuticals Inc stockChart Signals & Consistent Return Investment Signals - baoquankhu1.vn
Aug PreEarnings: What is Oramed Pharmaceuticals Incs 5 year growth outlookWeekly Profit Recap & Expert Curated Trade Setups - baoquankhu1.vn
Oramed Pharmaceuticals (ORMP) Leads Healthcare Dividend Yields - GuruFocus
Top 10 healthcare stocks with highest dividend yield amid volatile markets (ORMP:NASDAQ) - Seeking Alpha
DYCQ Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Dip Buying: Is Oramed Pharmaceuticals Inc stock a smart retirement pick2025 Growth vs Value & Safe Entry Trade Signal Reports - baoquankhu1.vn
Update Report: Can Oramed Pharmaceuticals Inc maintain sales growthShare Buyback & Accurate Buy Signal Alerts - baoquankhu1.vn
ORMP Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Short Interest in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Declines By 16.2% - MarketBeat
ORMP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
ORMP Technical Analysis & Stock Price Forecast - Intellectia AI
Guidance Update: Should you avoid Oramed Pharmaceuticals Inc stock right nowJuly 2025 Breakouts & Low Drawdown Investment Strategies - baoquankhu1.vn
Oramed Pharmaceuticals Inc Stock (ORMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.52%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):